Human Phospho-VEGFR2/KDR DuoSet IC ELISA DYC1766-2 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemHuman Phospho-VEGFR2/KDR DuoSet IC ELISA
CompanyR&D Systems, a Bio-Techne Brand
Price $495.00Supplier Page View Company Product Page
Catalog NumberDYC1766-2
Quantity1 Kit (for 2 Plates) (also 1 Kit (for 5 Plates), 1 Pack (for 15 Plates))
ApplicationsELISA
ReactivityHuman
Detection TargetVEGFR2/KDR/Flk-1
StorageStore the unopened product at 2 - 8 °C. Do not use past expiration date
NCBI Full Gene Namekinase insert domain receptor
NCBI Gene AliasesCD309, FLK1, VEGFR, VEGFR2

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(1) Clustered VEGF Nanoparticles in Microporous Annealed Particle (MAP) Hydrogel Accelerates Functional Recovery and Brain Tissue Repair after StrokebioRxiv : the preprint server for biologyFebruary 5, 2025Erning K, Wilson KL, Smith CS, Nguyen L, Joesph NI, Irengo R, Cao LY, Cumaran M, Shi Y, Lyu S, et al.

(2) Thiol-ene conjugation of VEGF peptide to electrospun scaffolds as potential application for angiogenesisBioactive materialsFebruary 1, 2023Yao T, Chen H, Wang R, Rivero R, Wang F, Kessels L, Agten SM, Hackeng TM, Wolfs TGAM, Fan D, et al.

(3) Dual Action of Sulfated Hyaluronan on Angiogenic Processes in Relation to Vascular Endothelial Growth Factor-AScientific reportsDecember 2, 2019Koehler L, Ruiz-Gómez G, Balamurugan K, Rother S, Freyse J, Möller S, Schnabelrauch M, Köhling S, Djordjevic S, Scharnweber D, et al.

(4) Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS StatusClinical cancer research : an official journal of the American Association for Cancer ResearchJune 1, 2018Mésange P, Bouygues A, Ferrand N, Sabbah M, Escargueil AE, Savina A, Chibaudel B, Tournigand C, André T, de Gramont A, et al.

(7) The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biologyThe Journal of biological chemistryMarch 22, 2013Harris NC, Davydova N, Roufail S, Paquet-Fifield S, Paavonen K, Karnezis T, Zhang YF, Sato T, Rothacker J, Nice EC, et al.

(8) AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase familyCancer researchApril 15, 2012Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, et al.

(9) Biomarkers for antitumor activity of bevacizumab in gastric cancer modelsBMC cancerJanuary 25, 2012Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K.

(10) The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domainFASEB journal : official publication of the Federation of American Societies for Experimental BiologyDecember 1, 2010Martino MM, Hubbell JA.

(11) Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3The Journal of cell biologyJanuary 11, 2010Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivée B, Del Toro R, Suchting S, Medvinsky A, et al.

(12) Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sproutingThe Journal of biological chemistryAugust 17, 2007Pan Q, Chathery Y, Wu Y, Rathore N, Tong RK, Peale F, Bagri A, Tessier-Lavigne M, Koch AW, Watts RJ.

(13) Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migrationBloodAugust 15, 2006Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, Mandron M, Herault JP, Neufeld G, Savi P, et al.

Phospho-VEGFR2/KDR/Flk-1 ELISA